Media Articles Related to Orap (Pimozide)
Source: MedicineNet Panic Disorder Specialty [2016.10.04]
Category: Diseases and Conditions
Created: 10/10/2002 12:00:00 AM
Last Editorial Review: 10/4/2016 12:00:00 AM
Study finds that belief that Tourette's patients are aggressive to be a myth
Source: ADHD / ADD News From Medical News Today [2016.09.19]
It is commonly believed that people with Tourette's syndrome tend to be aggressive.
Published Studies Related to Orap (Pimozide)
Efficacy of pimozide augmentation for clozapine partial responders with
INTRODUCTION: A substantial number of patients with treatment-resistant
schizophrenia respond only partially to clozapine... DISCUSSION: In this well controlled clinical trial of patients with
treatment-resistant schizophrenia currently receiving clozapine, pimozide
augmentation was not an effective strategy to maximize the benefit for better
control of positive and negative symptoms or improving neurocognitive function.
Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. [2011.05]
Despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics.However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted.
Quantitative determination of pimozide in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study. [2010.04.06]
A simple, sensitive and specific LC-ESI/MS method was developed for the determination of pimozide in human plasma. Pimozide and cinnarizine (internal standard) were isolated from plasma samples by liquid-liquid extraction...
Pimozide for tics in Tourette's syndrome. [2009.04.15]
CONCLUSIONS: Pimozide is an effective treatment for tics in Tourette Syndrome, though the number of trials comparing its effect to placebo and other drugs is limited. Trials of longer duration (minimum six months) are needed to investigate the longer-term effects of pimozide compared to atypical neuroleptics. Future trials should use the Yale Global Tic Severity Scale to assess the main outcome measure, and quantify adverse events with the Extrapyramidal Symptoms Rating Scale.
Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. [2005.02]
CONCLUSIONS: Pimozide augmentation of fluoxetine treatment for body dysmorphic disorder was not more effective than placebo, even in more delusional patients. Further studies of augmentation for SRIs are needed.
Clinical Trials Related to Orap (Pimozide)
Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia [Completed]
This study will assess the effectiveness of pimozide in enhancing the effects of clozapine
in the treatment of schizophrenia.
A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS [Recruiting]
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that results in rapid decline
in normal muscle function and tone leading to difficulties with mobility, eating, drinking,
breathing, sleeping, and communicating. The disease is progressive and no cure currently
exists. Most people diagnosed with ALS succumb within 3 to 5 years. The only approved
treatment to slow the progression of ALS is called RilutekŪ (riluzole) which has only a
modest effect and has been shown to increase survival by a few months.
Muscular dysfunction present in people with ALS is caused by nerve breakdown and a
dysfunction in the communication between the muscles and the nerves. The area where these
communications occur is called the neuromuscular junction. Some recent studies have focused
on using different medications to enhance communication at the neuromuscular junction with
the goal of improving muscle function as a result. This approach is unproven but may help
to slow the progression of the disease.
Pimozide is a medication that has been demonstrated to enhance communication at the
neuromuscular junction in fish and mice. This study will look at whether Pimozide may help
to slow the progression of ALS and how much medication needs to be taken to have an effect.
Efficacy of Pimozide Augmentation for Clozapine Partial Response [Completed]
This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but
continue to experience symptoms. The purpose of this project is to find out if small doses
of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing
symptoms (such as hearing voices, having trouble in organizing your thoughts, lack of
interest in life events and social activities), compared to placebo (an inactive substance,
"sugar pill"), when added to clozapine in patients with schizophrenia.
The participant will be asked to come in once a week to meet with the research staff and
study doctor. The participant will continue to see your regular clinician during this study
for all normal appointments. The participant will remain on your current medications
throughout the study. During the study you will be randomly selected to be put on a small
dose of Pimozide or placebo.
Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome [Completed]
OBJECTIVES: I. Determine whether the time period between randomization and endpoint is
longer in the short term pimozide therapy or longer term therapy in patients with Tourette
II. Determine whether tic severity, medication side effects, academic performance and
psychosocial functioning are better in the short term pimozide therapy or longer term
Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis [Recruiting]
The purpose of this study is to assess if patients who continue with antipsychotic treatment
for 12 or more months show the same risk of relapse (measured by PANSS) that patients with
the same medical condition who have followed a discontinuation treatment scheme based in the
presence of prodromes.
The candidates should accomplish the following criteria: first episode of non-affective
psychosis who have followed antipsychotic treatment for 12 months and who have already shown
Reports of Suspected Orap (Pimozide) Side Effects
Suicidal Ideation (3),
Inappropriate Antidiuretic Hormone Secretion (2),
Abdominal Pain (1), more >>